Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Randomized, Controlled, Observer-blind, Single-center Study to Evaluate the Immunogenicity, Safety and Tolerability of Two Doses of an H5N1 Influenza Vaccine in Subjects Aged 6 Months to 17 Years

NCT00537524 is registered in ClinicalTrials.gov with Novartis Vaccines as lead sponsor.

NCT NCT00537524
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00537524 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Randomized, Controlled, Observer-blind, Single-center Study to Evaluate the Immunogenicity, Safety and Tolerability of Two Doses of an H5N1 Influenza Vaccine in Subjects Aged 6 Months to 17 Years
Lead sponsor
Novartis Vaccines
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2007
Completion date
May 31, 2008
Enrollment
471 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prophylaxis of avian influenza